Physician profile
Mitchell M Pitlick
NPI 1073044574
$26,476.98
in general payments reported to CMS, 2019-2025
32 companies · $21K in 2025
The $21K reported for 2025 was more than what 92% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.65 · 2023: $1,442 · 2024: $4,152 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $9,518 · Consulting Fee: $1,415 · Education: $79.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,440.00 |
| Food and Beverage | $9,518.37 |
| Consulting Fee | $1,415.00 |
| Education | $79.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $19,093.14 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $1,712.92 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,412.09 | 2023-2025 | Hyqvia, Cuvitru, Eohilia |
| Csl Behring | $470.27 | 2023-2025 | Hizentra, Haegarda, Privigen |
| Glaxosmithkline, LLC. | $407.05 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $376.26 | 2023-2025 | Xolair |
| Amgen INC. | $349.54 | 2023-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $341.84 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $316.57 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $295.23 | 2023-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $244.98 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $178.05 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $160.96 | 2023-2025 | Orladeyo |
| Hospira, INC. | $152.31 | 2024-2025 | |
| Octapharma USA, INC. | $101.57 | 2023-2024 | Octagam Immune Globulin (Human) |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $92.83 | 2023-2025 | Adbry, Anzupgo |
| Pfizer INC. | $92.62 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $77.31 | 2024-2025 | Ryaltris |
| Blueprint Medicines Corporation | $75.68 | 2024-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Abbvie INC. | $68.58 | 2022-2024 | |
| Lilly USA, LLC | $67.29 | 2025 | Ebglyss, Taltz |
| Kaleo, INC. | $60.96 | 2023-2024 | Auvi-Q |
| Mylan Specialty L.P. | $55.60 | 2024 | Yupelri |
| Optinose US, INC. | $37.28 | 2024-2025 | |
| Organon LLC | $33.56 | 2025 | Vtama |
| Ionis Pharmaceuticals, INC. | $30.38 | 2025 | Dawnzera |
| Horizon Therapeutics Plc | $22.20 | 2023 | Actimmune |
| Galderma Laboratories, L.P. | $22.04 | 2025 | Nemluvio |
| Incyte Corporation | $20.45 | 2024 | Opzelura |
| Cycle Pharmaceuticals INC | $18.32 | 2025 | Sajazir |
| Seqirus USA INC | $17.10 | 2025 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Pitlick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.